Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merck

78.97
+1.351.74%
Post-market: 79.000.0300+0.04%19:57 EDT
Volume:9.86M
Turnover:778.72M
Market Cap:198.30B
PE:11.48
High:79.49
Open:78.30
Low:78.21
Close:77.62
Loading ...

Merck Held Talks to Buy Swiss Biotech MoonLake for More Than $3Bn- FT

THOMSON REUTERS
·
03 Jun

Merck, Gilead Combination Reduces Disease-Progression Risk of Breast Cancer in Phase 3 Study

MT Newswires Live
·
02 Jun

Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?

Motley Fool
·
02 Jun

Merck announces data from trial studying KEYTRUDA plus Trodelvy

TIPRANKS
·
02 Jun

Gilead announces data on Trodelvy plus Keytruda

TIPRANKS
·
02 Jun

Keytruda® (Pembrolizumab) Plus Trodelvy® (Sacituzumab Govitecan-Hziy) Reduced Risk of Disease Progression or Death by 35% Versus Keytruda Plus Chemotherapy in First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer (Tnbc)

THOMSON REUTERS
·
31 May

Merck & Co Inc - Keytruda Plus Trodelvy Shows 11.2 Months Median Pfs Versus 7.8 Months With Chemotherapy

THOMSON REUTERS
·
31 May

New Hope for Strokes And Heart Attacks -- Barron's

Dow Jones
·
31 May

Walmart, Amgen Share Gains Contribute To Dow's 100-Point Jump

Dow Jones
·
31 May

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down. -- Barrons.com

Dow Jones
·
30 May

BRIEF-Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor

Reuters
·
30 May

Merck announces results from dose confirmation part of Phase 2/3 waveLINE-003

TIPRANKS
·
30 May

BRIEF-Merck’S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity

Reuters
·
30 May

Merck's Investigational Drug MK-1084 Shows Promising Antitumor Activity in Early Trial for Advanced Colorectal and Lung Cancers

Reuters
·
30 May

Merck & Co Inc - Mk-1084 to Be Investigated in Phase 3 Kandlelit-012 and Kandlelit-004 Studies

THOMSON REUTERS
·
30 May

Merck & Co Inc - Mk-1084 Shows Manageable Safety Profile and Antitumor Activity

THOMSON REUTERS
·
30 May

Merck Announces Mk-1084, an Investigational Kras G12c Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor Kras G12c Mutations

THOMSON REUTERS
·
30 May

Merck's Zilovertamab Vedotin Shows Promising Results in Phase 2 Trial for Relapsed/Refractory DLBCL at 2025 ASCO Meeting

Reuters
·
30 May

Merck’s Investigational Zilovertamab Vedotin at 1.75 Mg/Kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory Dlbcl in Phase 2 Portion of Waveline-003 Trial

THOMSON REUTERS
·
30 May

Merck & Co Inc - Zilovertamab Vedotin Under Evaluation in Phase 3 and Phase 2 Studies

THOMSON REUTERS
·
30 May